Last checked at 25 May 2021 21:26
IN BRIEF: Crossword Cybersecurity bolsters board with two appointments
IN BRIEF: Crossword Cybersecurity bolsters board with two appointments
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades6,322
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,799.50
Bid:
1,796.00
Ask:
1,796.50
Change:
19.00 (1.07%)
Spread:
0.50 (0.028%)
Open:
1,784.00
High:
1,799.50
Low:
1,780.00
Prev. Close:
1,780.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.25 May 2021 13:07
Tuesday broker round-up
(Sharecast News) - Travis Perkins: Deutsche Bank resumes coverage with a recommendation to hold and a target price of 1,707p.
Read more21 May 2021 16:11
EMA gives 'thumbs up' for GSK Covid-19 treatment sotrovimab
(Sharecast News) - The European Medicines Agency's Committee for Human Medicinal Products issued a 'positive scientific opinion' for the Covid-19 treatment developed by GlaxoSmithKline and Vir Biotechnology, sotrovimab.
Read more21 May 2021 13:45
IN BRIEF: GlaxoSmithKline's sotrovimab gets EMA positive opinion
IN BRIEF: GlaxoSmithKline's sotrovimab gets EMA positive opinion
Read more20 May 2021 15:43
UPDATE 2-Britain's GSK exits U.S. drugmaker Innoviva in $392 million deal
* GSK sells 32% stake in product portfolio company* Innoviva was separated from Theravance in 2014* GSK says royalty agreements with Innoviva unchanged (Adds details on Innoviva)May 20 (Reuters) - GlaxoSmithKline has sold its entire stake in Innovi...
Read more20 May 2021 15:16
GlaxoSmithKline sells entire Innoviva stake for USD392 million
GlaxoSmithKline sells entire Innoviva stake for USD392 million
Read more18 May 2021 10:53
UPDATE 1-Novartis to close Spanish site in revamp of European antibiotics production
(Adds background, comment from Sandoz CEO)ZURICH, May 18 (Reuters) - Swiss drugmaker Novartis's Sandoz generics unit will close one Spanish site, expand another and proceed with a new Austrian facility, it said on Tuesday, as it revamps its Europe...
Read more18 May 2021 09:06
TOP NEWS: GlaxoSmithKline and Medicago hail Covid-19 vaccine results
TOP NEWS: GlaxoSmithKline and Medicago hail Covid-19 vaccine results
Read more18 May 2021 08:21
LONDON BRIEFING: Vodafone shares slide 6% after annual revenue decline
LONDON BRIEFING: Vodafone shares slide 6% after annual revenue decline
Read more18 May 2021 08:18
GlaxoSmithKline reveals positive interim Phase 2 results for Covid-19 vaccine candidate
(Sharecast News) - Pharmaceutical company GlaxoSmithKline has revealed positive interim Phase 2 results for its adjuvanted Covid-19 vaccine candidate, developed in partnership with Canadian biopharmaceutical firm Medicago.
Read more17 May 2021 10:52
TOP NEWS SUMMARY: China factory output booms but retail sales trail
TOP NEWS SUMMARY: China factory output booms but retail sales trail
Read more17 May 2021 09:43
UPDATE 2-European stocks end flat between Asia worries, British re-opening cheer
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Asia restrictions, China data weigh* Kinnevik jumps to top of STOXX 600* Spain's Telefonica gains as it seeks buyers for delivery arm* San...
Read more17 May 2021 07:33
GSK Covid-19 achieves 'strong' results in Phase 2 study
(Sharecast News) - GlaxoSmithKline said its Covid-19 vaccine achieved strong results in a Phase 2 study and would start a global Phase 3 study in the next few weeks.
Read more17 May 2021 06:57
Sanofi and GSK's Covid vaccine candidate shows strong immune response
Sanofi and GSK's Covid vaccine candidate shows strong immune response
Read more17 May 2021 06:51
UPDATE 3-Sanofi-GSK report positive interim results for their COVID-19 shot
* Interim results show 95-100% seroconversion after second shot* Vaccine has universal booster potential -Sanofi (Adds quote, shares, detail)By Matthias BlamontPARIS, May 17 (Reuters) - An experimental COVID-19 vaccine developed by Sanofi and Glax...
Read more